Novo Nordisk A Slash S Sustainability Profile
Novo Nordisk A/S, headquartered in Denmark (DK), is a global leader in the pharmaceutical industry, specialising in diabetes care, obesity management, and hormone replacement therapies. Founded in 1923, the company has achieved significant milestones, including the development of innovative insulin products and GLP-1 receptor agonists that have transformed diabetes treatment. With a strong presence in Europe, North America, and Asia, Novo Nordisk is renowned for its commitment to sustainability and patient-centric solutions. Its core products, such as insulin pens and diabetes management devices, are distinguished by their advanced technology and user-friendly design. As a pioneer in diabetes care, Novo Nordisk holds a prominent market position, consistently recognised for its contributions to improving patient outcomes and advancing healthcare globally.
DitchCarbon Score
How does Novo Nordisk A Slash S's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Novo Nordisk A Slash S's score of 73 is higher than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Novo Nordisk A Slash S's reported carbon emissions
In 2024, Novo Nordisk A/S reported total carbon emissions of approximately 2,261,000,000 kg CO2e. This includes Scope 1 emissions of about 85,000,000 kg CO2e, Scope 2 emissions of approximately 16,000,000 kg CO2e, and significant Scope 3 emissions totalling around 2,160,000,000 kg CO2e. The Scope 3 emissions breakdown reveals major contributions from purchased goods and services (about 1,215,000,000 kg CO2e) and capital goods (approximately 465,000,000 kg CO2e). The company has set ambitious climate commitments, aiming for net-zero emissions across its entire value chain by 2045. Near-term targets include a 100% reduction in absolute Scope 1 and 2 emissions by 2030, using 2024 as the base year. Additionally, Novo Nordisk aims to reduce its absolute Scope 3 emissions by 33% by 2033, compared to the same base year. These targets align with the Science Based Targets initiative (SBTi) and reflect a commitment to maintaining a minimum of 100% reduction in Scope 1 and 2 emissions from 2030 through 2045, while also targeting a 90% reduction in Scope 3 emissions by 2045. The company’s proactive approach underscores its dedication to sustainability within the pharmaceutical sector, headquartered in Denmark (DK).
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 86,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 75,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Novo Nordisk A Slash S's Industry?
How Carbon Intensive is Novo Nordisk A Slash S's Location?
Novo Nordisk A Slash S's Scope 3 Categories Breakdown
Novo Nordisk A Slash S's Scope 3 emissions, which increased by 24% last year and increased by approximately 24% since 2023, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 56% of Scope 3 emissions.
Top Scope 3 Categories
Novo Nordisk A Slash S's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Novo Nordisk A Slash S has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Frequently Asked Questions
Common questions about Novo Nordisk A Slash S's sustainability data and climate commitments